Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 69
- Press Release
- Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403
- (์ฃผ)ํ๋ฉฅ์
- 18 Dec 2025
- Views673
- 0
- 68
- Press Release
- Press Release PharmAbcineโs PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (์ฃผ)ํ๋ฉฅ์
- 21 Aug 2025
- Views2616
- 0
- 67
- Press Release
- Press Release PharmAbcineโs PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (์ฃผ)ํ๋ฉฅ์
- 19 May 2025
- Views3585
- 0
- 66
- Press Release
- Press Release PharmAbcine at JP Morgan Healthcare Conference 2025
- (์ฃผ)ํ๋ฉฅ์
- 10 Jan 2025
- Views4781
- 0
- 65
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- (์ฃผ)ํ๋ฉฅ์
- 9 Jan 2025
- Views4104
- 0
- 64
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- PharmAbcine
- 16 Oct 2024
- Views4378
- 0
- 63
- Press Release
- Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
- PharmAbcine
- 9 Jul 2024
- Views5147
- 0
- 62
- Press Release
- Press Release PharmAbcineโs Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
- PharmAbcine
- 2 Jul 2024
- Views4735
- 0
- 61
- Press Release
- Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
- PharmAbcine
- 23 May 2024
- Views5024
- 0
